Full Press Release Details
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. Dr. Redfield brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health. He has authored an extensive body of scientific liter